Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2497–2520 of 33,183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: placebo Clear all

Conditions: Healthy
Interventions: placebo, lixivaptan, moxifloxacin; Drug
Lead sponsor: CardioKine Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 298 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Diabetes Mellitus Type 2
Interventions: androgel, androgel 10g, placebo; Drug
Lead sponsor: University at Buffalo; Other
Eligibility: 35 Years to 75 Years · Male only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: COVID-19 Pneumonia, Acute Lung Injury, ARDS
Interventions: CERC-002, Placebo; Drug
Lead sponsor: Aevi Genomic Medicine, LLC, a Cerecor company; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 11
States / cities: Newport Beach, California • Ft. Pierce, Florida • West Palm Beach, Florida + 8 more

Conditions: Alcohol Drinking
Interventions: Alcohol, Placebo; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 21 Years to 35 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pain
Interventions: Transcutaneous Electrical Nerve Stimulation (TENS); Device
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: New Haven, Connecticut

Conditions: Bowel Dysfunction, Constipation
Interventions: Alvimopan, Placebo; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 805 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 143
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 120 more

Conditions: NASH, Cirrhosis, Liver
Interventions: Resmetirom, Placebo; Drug
Lead sponsor: Madrigal Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 845 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 96
States / cities: Birmingham, Alabama • Chandler, Arizona • Peoria, Arizona + 76 more

Conditions: Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
Interventions: Cotadutide, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 29
States / cities: Tucson, Arizona • Canoga Park, California • Gilroy, California + 23 more

Conditions: Post-Traumatic Stress Disorder (PTSD)
Interventions: Oxytocin nasal spray, Saline nasal spray, Brief Cognitive-Behavioral Conjoint Therapy; Drug · Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: San Diego, California

Conditions: Breast Neoplasms
Interventions: Pumitamig, Nab-paclitaxel/Paclitaxel, Gemcitabine, Carboplatin, Eribulin, Matching placebo; Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 558 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 71
States / cities: Springdale, Arkansas • La Jolla, California • Los Alamitos, California + 56 more

Conditions: Tonsillectomy
Interventions: Intravenous ibuprofen, Normal Saline; Drug · Other
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 6
States / cities: Louisville, Kentucky • Newark, New Jersey • Charlotte, North Carolina + 3 more

Conditions: Glutathione-cyclodextrin Complex Absorption
Interventions: Glutaryl Solution, Placebo Solution; Dietary Supplement
Lead sponsor: Western University of Health Sciences; Other
Eligibility: 21 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Pomona, California

Conditions: Pulmonary Arterial Hypertension
Interventions: Esuberaprost, Placebo; Drug
Lead sponsor: Lung Biotechnology PBC; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 43
States / cities: Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 37 more

Conditions: Carcinoma, Renal Cell
Interventions: Belzutifan, Zanzalintinib, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 758 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 14
States / cities: Duarte, California • Irvine, California • Marietta, Georgia + 9 more

Conditions: Healthy Volunteers, Sickle Cell Disease
Interventions: FT-4202/Placebo; Drug
Lead sponsor: Forma Therapeutics, Inc.; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 18
States / cities: Little Rock, Arkansas • Long Beach, California • Oakland, California + 12 more

Conditions: Peanut Allergy
Interventions: ASP0892 Intradermal, ASP0892 Intramuscular, Placebo Intradermal, Placebo Intramuscular; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 8
States / cities: Little Rock, Arkansas • Mountain View, California • Baltimore, Maryland + 5 more

Conditions: Hypertrophic Scar
Interventions: RXI-109, Placebo; Drug
Lead sponsor: RXi Pharmaceuticals, Corp.; Industry
Eligibility: 21 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 4
States / cities: Lake Worth, Florida • Chicago, Illinois • St Louis, Missouri + 1 more

Conditions: Obesity, Insulin Resistance, Hypertension, Metabolic Cardiovascular Syndrome
Interventions: Angiotensin-(1-7), Saline; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Nasal Polyps
Interventions: GSK5784283, Placebo, Standard of Care; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Sherman Oaks, California • Greenville, South Carolina • Plano, Texas

Conditions: Asthma
Interventions: RNS60, Normal Saline, Budesonide; Drug
Lead sponsor: Revalesio Corporation; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 4
States / cities: Costa Mesa, California • Los Angeles, California • Riverside, California

Conditions: Giant Cell Arteritis
Interventions: Tocilizumab, Prednisone, Tocilizumab Placebo, Prednisone Placebo, Corticosteroids, Methotrexate; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years and older
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 14
States / cities: Los Angeles, California • Boca Raton, Florida • Sarasota, Florida + 10 more

Conditions: Japanese Encephalitis
Interventions: ChimeriVax™-JE, JE-VAX®; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 820 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 5
States / cities: Chicago, Illinois • Shawnee Mission, Kansas • Missoula, Montana + 2 more

Conditions: Hyperhidrosis
Interventions: WL8713, 6 mg, WL8713, 12 mg, WL8713, 18 mg, WL8713, 24 mg, Placebo; Drug
Lead sponsor: Watson Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: San Diego, California

Conditions: Migraine Headache
Interventions: Psilocybin, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: West Haven, Connecticut

Search by objective public record fields.

A Study to Define the ECG Effects of Lixivaptan Compared to Placebo and Moxifloxacin in Healthy Adult Men and Women: A Thorough ECG Study

Effect of Androgel on Type 2 Diabetic Males With Hypogonadism

Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury

Social Effects of Alcohol

Transcutaneous Electrical Nerve Stimulation (TENS) for Intrauterine Device (IUD) Insertion Pain

Long-Term Safety Evaluation Of Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain

A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

Examining Intranasal Oxytocin Augmentation of Brief Couples Therapy for Veterans With PTSD

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

Safety and Efficacy of Intravenous Ibuprofen for Treatment of Pain in Pediatric Patients Undergoing Tonsillectomy

Topical Absorption of Glutathione-cyclodextrin Complex in Healthy Human Subjects Improves Immune Response Against Mycobacterium Infection

A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension

A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)

A SAD/MAD to Assess the Safety, PK/PD of FT-4202 in Healthy Volunteers and Sickle Cell Disease Patients

A Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine

A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery in Healthy Adults

Metabolic Effects of Angiotensin-(1-7)

A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

Study of Inhaled RNS60 in Combination With Budesonide to Treat Mild to Moderate Asthma

An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA)

A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX

Safety and Efficacy of an Anticholinergic Agent for Treatment of Primary Axillary Hyperhidrosis

Repeat Dosing of Psilocybin in Migraine Headache